At the University of Birmingham our research leads to new inventions and fuels innovation and business growth.
Prostate cancer is one of the most common types of cancer in men and claims over 300,000 lives worldwide every year. Early and accurate detection is critical to improve patient survival. However, current diagnostic procedures are either invasive and expensive or – in the case of current antigen based testing – lacking in accuracy.
Scientists at the University of Birmingham have created synthetic receptors at nano-cavies on surfaces that are complementary in size, shape and functional group orientation to the target glycoprotein. The sensor chip integrates seamlessly with existing SPR technology already available in many medical and biological laboratory scenarios.
The new sensor chips offer significant advantages over the currently predominant antigen reliant diagnostic technology.